AEON Biopharma terminated the Consulting Agreement with Peter Reynolds, resulting in his resignation as CFO, principal financial officer, and principal accounting officer. Marc Forth was appointed as the new principal financial officer, and Jennifer Sy was appointed as the principal accounting officer. AEON also terminated its Phase 2 double blind study of ABP-450 in the treatment of migraine and its open label extension study.